Drug lookup
Drug reference

Sulfamethoxazole

Sulfonamide · Antibiotic

Also known as Co-trimoxazole

SulfonamideAntibioticATC J01EE01
CDSCO approvedSchedule HATC J01EE01
EXCRETION
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12
  • Aminobenzoic AcidSevereDatabaseDDInter
  • Aminolevulinic AcidSevereDatabaseDDInter
  • AnisindioneSevereDatabaseDDInter
  • ClozapineSevereDatabaseDDInter

Mechanism

Sulfamethoxazole, as a sulfonamide, works by inhibiting bacterial dihydrofolate synthesis. When combined with trimethoprim, it exhibits synergistic activity through sequential blockade of the bacterial folate synthesis pathway, leading to an enhanced antibacterial effect.

Indications

Treatment of susceptible infectionsModerate diabetic foot infectionSevere diabetic foot infectionLeg ulcer infectionHospital-acquired pneumoniaAcute exacerbation of chronic obstructive pulmonary diseaseHIV infection management (in combination with trimethoprim and antiretroviral agents)Small intestinal bacterial overgrowth (SIBO)Systemic infections (usually in fixed-dose combination with trimethoprim)Urinary tract infections (usually in fixed-dose combination with trimethoprim)combination with trimethoprim (cotrimoxazole)

Dosing

Adult
Treatment of susceptible infections: By mouth, 960 mg twice daily; By intravenous infusion, 960 mg every 12 hours, increased to 1.44 g every 12 hours in severe infection. Moderate/Severe diabetic foot infection: By mouth, 960 mg twice daily; By intravenous infusion, 960 mg every 12 hours, increased if necessary to 1.44 g every 12 hours.…
Pediatric
Child 6 weeks–5 months: 120 mg twice daily, alternatively 24 mg/kg twice daily. Child 6 months–5 years: 240 mg twice daily, alternatively 24 mg/kg twice daily. Child 6–11 years: 480 mg twice daily, alternatively 24 mg/kg twice daily. Child 12–17 years: 960 mg twice daily.
Renal adjustment
Usual initial dose, then use half normal dose if eGFR 20–50 mL/minute/1.73 m2; 100 mg every 24 hours if eGFR less than 20 mL/minute/1.73 m2.
Hepatic adjustment
Manufacturer advises caution; maximum 400 mg daily in hepatic failure (risk of decreased elimination).

Pharmacokinetics

Onset
slower oral absorption
Half-life
10 hours
Bioavailability
100%
Protein binding
62%
Metabolism
high fraction is acetylated (acetylated derivative is relatively insoluble)
Excretion
14%

Contraindications

  • risk of crystalluria

Side effects

Common
NauseaVomitingHeadacheGI disturbancesAbdominal painAnorexiacrystalluriaHypersensitivity reactions (allergy usually associated with sulfonamide moiety)Gastrointestinal effectsallergic skin reactions
Serious
  • Enterocolitis (rare or very rare)
  • Haemorrhagic enterocolitis (rare or very rare)
  • Bone marrow failure (frequency not known)
  • Myopathy (frequency not known)
  • Acute interstitial nephritis (frequency not known)
  • Crystalluria
  • Nephrotoxicity
  • Hematologic effects (leukopenia, thrombocytopenia, granulocytopenia)
  • Risk in third trimester of pregnancy
  • severe skin reactions (toxic epidermal necrolysis, erythema multiforme, stevens-johnson syndrome)
  • agranulocytosis
  • aplastic anemia
  • hypersensitivity of the respiratory tract
  • hepatitis
  • interstitial nephritis
  • hypoglycemia
  • aseptic meningitis

Pregnancy & lactation

Pregnancy

D

Lactation

Amount probably too small to be harmful but manufacturer advises avoid.

Drug interactions

Aminobenzoic Acid
Severe
Database

Drug interaction classified as: antagonism

Source: DDInter

Aminolevulinic Acid
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Anisindione
Severe
Database

Drug interaction classified as: distribution, metabolism

Source: DDInter

Clozapine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Cyclosporine
Severe
Database

.

Source: DDInter

Dicoumarol
Severe
Database

Clinical effect not specified

Source: DDInter

Lomitapide
Severe
Database

Clinical effect not specified

Source: DDInter

Methenamine
Severe
Database

Clinical effect not specified

Source: DDInter

Mipomersen
Severe
Database

Clinical effect not specified

Source: DDInter

Nitrous Acid
Severe
Database

Clinical effect not specified

Source: DDInter

Pexidartinib
Severe
Database

Clinical effect not specified

Source: DDInter

Prilocaine
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Other Sulfonamide drugs

Ask House about Sulfamethoxazole

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e, Katzung·Verified: 2026-05-13 · House clinical team